Erica C. Nakajima

Oncology

201 N Broadway St
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.

Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 03, 2025

[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.

[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 16, 2024

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.

Journal: JCO precision oncology

Published: April 18, 2024

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 11, 2021

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 27, 2021

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.

Journal: The oncologist

Published: March 25, 2021

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event.

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 29, 2019

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas.

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas.

Journal: PloS one

Published: October 26, 2017

Heart in Hand.

Heart in Hand.

Journal: Annals of internal medicine

Published: October 20, 2017

A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma.

A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma.

Journal: Kidney cancer (Clifton, Va.)

Published: July 26, 2017

Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions.

Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions.

Journal: PloS one

Published: March 29, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026